Connection

William Hrushesky to Humans

This is a "connection" page, showing publications William Hrushesky has written about Humans.
Connection Strength

0.815
  1. Reimagining Cancer: Moving from the Cellular to the Tissue Level. Cancer Res. 2023 01 18; 83(2):173-180.
    View in: PubMed
    Score: 0.032
  2. Interpretation of surrogate endpoints in the era of the 21st Century Cures Act. BMJ. 2016 Dec 30; 355:i6286.
    View in: PubMed
    Score: 0.021
  3. Cancer as a changed tissue's way of life (when to treat, when to watch and when to think). Future Oncol. 2016 Mar; 12(5):647-57.
    View in: PubMed
    Score: 0.020
  4. Measuring stem cell circadian rhythm. Methods Mol Biol. 2015; 1235:81-95.
    View in: PubMed
    Score: 0.018
  5. Correspondence. J Natl Compr Canc Netw. 2012 Jul 01; 10(7):xxxvii.
    View in: PubMed
    Score: 0.016
  6. Guideline-based peer-to-peer consultation optimizes pegfilgrastim use with no adverse clinical consequences. Am J Manag Care. 2012 05 01; 18(5):e168-72.
    View in: PubMed
    Score: 0.015
  7. The association of quality of life with potentially remediable disruptions of circadian sleep/activity rhythms in patients with advanced lung cancer. BMC Cancer. 2011 May 23; 11:193.
    View in: PubMed
    Score: 0.014
  8. Sunspot dynamics are reflected in human physiology and pathophysiology. Astrobiology. 2011 Mar; 11(2):93-103.
    View in: PubMed
    Score: 0.014
  9. Global breast cancer seasonality. Breast Cancer Res Treat. 2010 Aug; 123(1):233-43.
    View in: PubMed
    Score: 0.013
  10. Actigraphic assessment of daily sleep-activity pattern abnormalities reflects self-assessed depression and anxiety in outpatients with advanced non-small cell lung cancer. Psychooncology. 2010 Feb; 19(2):180-9.
    View in: PubMed
    Score: 0.013
  11. Mammalian TIMELESS is required for ATM-dependent CHK2 activation and G2/M checkpoint control. J Biol Chem. 2010 Jan 29; 285(5):3030-4.
    View in: PubMed
    Score: 0.013
  12. Circadian disruption, Per3, and human cytokine secretion. Integr Cancer Ther. 2009 Dec; 8(4):329-36.
    View in: PubMed
    Score: 0.013
  13. Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. Integr Cancer Ther. 2009 Dec; 8(4):387-97.
    View in: PubMed
    Score: 0.013
  14. The circadian clock gene Per1 suppresses cancer cell proliferation and tumor growth at specific times of day. Chronobiol Int. 2009 Oct; 26(7):1323-39.
    View in: PubMed
    Score: 0.013
  15. Beta-catenin induces beta-TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice. J Biochem. 2009 Mar; 145(3):289-97.
    View in: PubMed
    Score: 0.012
  16. Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res. 2008 Nov; 6(11):1786-93.
    View in: PubMed
    Score: 0.012
  17. Re: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007 Jul 04; 99(13):1053; author reply 1053-4.
    View in: PubMed
    Score: 0.011
  18. Enhanced surgery-induced angiogenesis among premenopausal women might partially explain excess breast cancer mortality of blacks compared to whites: an hypothesis. Int J Surg. 2007 Oct; 5(5):300-4.
    View in: PubMed
    Score: 0.011
  19. Chronotherapy of ovarian cancer: effect on blood variables and serum cytokines. A case report. Clin Ter. 2006 Jul-Aug; 157(4):349-54.
    View in: PubMed
    Score: 0.010
  20. Screening and breast cancer. N Engl J Med. 2006 Feb 16; 354(7):767-9; author reply 767-9.
    View in: PubMed
    Score: 0.010
  21. Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer. 2005 Nov 28; 93(11):1202-8.
    View in: PubMed
    Score: 0.010
  22. Sun exposure, sexual behavior and uterine cervical human papilloma virus. Int J Biometeorol. 2006 Jan; 50(3):167-73.
    View in: PubMed
    Score: 0.010
  23. Season, sun, sex, and cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005 Aug; 14(8):1940-7.
    View in: PubMed
    Score: 0.010
  24. Sex cycle modulates cancer growth. Breast Cancer Res Treat. 2005 May; 91(1):95-102.
    View in: PubMed
    Score: 0.009
  25. A recent illustration of some essentials of circadian chronotherapy study design. J Clin Oncol. 2004 Jul 15; 22(14):2971-2; author reply 2972.
    View in: PubMed
    Score: 0.009
  26. Re: Melatonin and breast cancer: a prospective study. J Natl Cancer Inst. 2004 Jun 02; 96(11):888-9.
    View in: PubMed
    Score: 0.009
  27. Circadian timing in cancer treatment: the biological foundation for an integrative approach. Integr Cancer Ther. 2003 Jun; 2(2):105-11.
    View in: PubMed
    Score: 0.008
  28. Breast cancer screening: controversies and future directions. Curr Opin Obstet Gynecol. 2003 Feb; 15(1):1-8.
    View in: PubMed
    Score: 0.008
  29. Androgen suppression and irradiation for locally advanced prostate cancer. Lancet. 2002 Dec 14; 360(9349):1987; author reply 1987-8.
    View in: PubMed
    Score: 0.008
  30. Breast cancer screening for women aged 40-49 years: screening may not be the benign process usually thought. J Natl Cancer Inst. 2001 Oct 17; 93(20):1572.
    View in: PubMed
    Score: 0.007
  31. Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. Lancet Haematol. 2021 Aug; 8(8):e593-e604.
    View in: PubMed
    Score: 0.007
  32. Wounding from biopsy and breast-cancer progression. Lancet. 2001 Mar 31; 357(9261):1048.
    View in: PubMed
    Score: 0.007
  33. The First 2?Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist. 2021 08; 26(8):e1418-e1426.
    View in: PubMed
    Score: 0.007
  34. Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat. 2001 Feb; 65(3):217-24.
    View in: PubMed
    Score: 0.007
  35. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
    View in: PubMed
    Score: 0.007
  36. Interpreting Breast Cancer Survival Data by the Hazard Function: Remarkable Findings from Event Dynamics. Medicina (Kaunas). 2020 Sep 12; 56(9).
    View in: PubMed
    Score: 0.007
  37. Rhythmic menstrual cycle modulation of breast cancer biology. J Surg Oncol. 2000 Jul; 74(3):238-41.
    View in: PubMed
    Score: 0.007
  38. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15(6):e0234541.
    View in: PubMed
    Score: 0.007
  39. Investigation of the comparative toxicity of 5-FU bolus versus 5-FU continuous infusion circadian chemotherapy with concurrent radiation therapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2000 Mar 01; 46(4):873-81.
    View in: PubMed
    Score: 0.007
  40. End of an era for erythropoiesis-stimulating agents in oncology. Int J Cancer. 2020 05 15; 146(10):2829-2835.
    View in: PubMed
    Score: 0.007
  41. Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions. PLoS One. 2019; 14(7):e0219521.
    View in: PubMed
    Score: 0.006
  42. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
    View in: PubMed
    Score: 0.006
  43. Evidence for an ontogenetic basis for circadian coordination of cancer cell proliferation. J Natl Cancer Inst. 1998 Oct 07; 90(19):1480-4.
    View in: PubMed
    Score: 0.006
  44. Menstrual timing of breast cancer surgery. Am J Surg. 1998 Mar; 175(3):245-61.
    View in: PubMed
    Score: 0.006
  45. Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR). Cancer Med. 2017 Jul; 6(7):1541-1551.
    View in: PubMed
    Score: 0.005
  46. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
    View in: PubMed
    Score: 0.005
  47. Circadian time structure of septic shock: timing is everything. J Infect Dis. 1997 May; 175(5):1283-4.
    View in: PubMed
    Score: 0.005
  48. Generic oncology drugs: are they all safe? Lancet Oncol. 2016 Nov; 17(11):e493-e501.
    View in: PubMed
    Score: 0.005
  49. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. Br J Haematol. 2018 01; 180(2):301-304.
    View in: PubMed
    Score: 0.005
  50. Menstrual cycle timing of breast cancer resection. Recent Results Cancer Res. 1996; 140:27-40.
    View in: PubMed
    Score: 0.005
  51. Circadian rhythms and cancer chemotherapy. Crit Rev Eukaryot Gene Expr. 1996; 6(4):299-343.
    View in: PubMed
    Score: 0.005
  52. Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.
    View in: PubMed
    Score: 0.005
  53. Erythropoietin usage in patients with cancer. Cancer J Sci Am. 1995 Nov-Dec; 1(4):243-6.
    View in: PubMed
    Score: 0.005
  54. Square pegs in round holes. Int J Cancer. 1995 Sep 04; 62(5):651-2.
    View in: PubMed
    Score: 0.005
  55. Adding Bevacizumab to the Treatment of Patients With Non-Small-Cell Lung Cancer: Caveat Emptor. J Oncol Pract. 2015 Sep; 11(5):363-4.
    View in: PubMed
    Score: 0.005
  56. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995 Apr; 95(4):1650-9.
    View in: PubMed
    Score: 0.005
  57. Menstrual cycle timing of breast cancer resection: prospective study is overdue. J Natl Cancer Inst. 1995 Jan 18; 87(2):143-4.
    View in: PubMed
    Score: 0.005
  58. Larry Scheving and cancer chronotherapy. J Infus Chemother. 1995; 5(1):1-2.
    View in: PubMed
    Score: 0.005
  59. Cancer chronotherapy: is there a right time in the day to treat? J Infus Chemother. 1995; 5(1):38-43.
    View in: PubMed
    Score: 0.005
  60. Biological perspectives on circadian cancer therapy. J Infus Chemother. 1995; 5(4):182-90.
    View in: PubMed
    Score: 0.005
  61. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014 Dec; 15(13):e594-e605.
    View in: PubMed
    Score: 0.005
  62. The Department of Veterans Affairs' unique clinical cancer research effort. Cancer. 1994 Nov 01; 74(9 Suppl):2701-9.
    View in: PubMed
    Score: 0.005
  63. Mammography and the menstrual cycle. Int J Cancer. 1994 Oct 01; 59(1):151.
    View in: PubMed
    Score: 0.005
  64. Circadian pharmacodynamics of anticancer therapies. Clin Chem. 1993 Nov; 39(11 Pt 2):2413-8.
    View in: PubMed
    Score: 0.004
  65. Circadian cancer therapy. J Clin Oncol. 1993 Jul; 11(7):1403-17.
    View in: PubMed
    Score: 0.004
  66. Breast cancer and the menstrual cycle. J Surg Oncol. 1993 May; 53(1):1-3.
    View in: PubMed
    Score: 0.004
  67. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Curr Med Chem. 2013; 20(33):4163-76.
    View in: PubMed
    Score: 0.004
  68. Circadian cancer pharmacodynamics. Ann Ist Super Sanita. 1993; 29(4):705-10.
    View in: PubMed
    Score: 0.004
  69. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. Breast Cancer Res Treat. 2012 Jul; 134(2):881-8.
    View in: PubMed
    Score: 0.004
  70. Optimal timing of initial breast cancer surgery. Ann Intern Med. 1992 Feb 01; 116(3):268.
    View in: PubMed
    Score: 0.004
  71. Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. Circulation. 1991 Aug; 84(2):697-707.
    View in: PubMed
    Score: 0.004
  72. Reprogramming SynchroMed pumps: unanticipated inaccuracy. J Clin Oncol. 1991 Jun; 9(6):1089-90.
    View in: PubMed
    Score: 0.004
  73. The multifrequency (circadian, fertility cycle, and season) balance between host and cancer. Ann N Y Acad Sci. 1991; 618:228-56.
    View in: PubMed
    Score: 0.004
  74. Temporally optimizable delivery systems--sine qua non for molecular medicine. Preface. Ann N Y Acad Sci. 1991; 618:xi-xvii.
    View in: PubMed
    Score: 0.004
  75. The effect of surgical timing within the fertility cycle on breast cancer outcome. Ann N Y Acad Sci. 1991; 618:277-91.
    View in: PubMed
    Score: 0.004
  76. Quantitative respiratory sinus arrhythmia analysis. A simple noninvasive, reimbursable measure of cardiac wellness and dysfunction. Ann N Y Acad Sci. 1991; 618:67-101.
    View in: PubMed
    Score: 0.004
  77. Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast. BMC Cancer. 2010 Nov 30; 10:656.
    View in: PubMed
    Score: 0.003
  78. Prohibitin as an oxidative stress biomarker in the eye. Int J Biol Macromol. 2010 Dec 01; 47(5):685-90.
    View in: PubMed
    Score: 0.003
  79. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol. 1990 Sep; 8(9):1504-13.
    View in: PubMed
    Score: 0.003
  80. Health care for US veterans and others. Lancet. 1990 Jul 21; 336(8708):182.
    View in: PubMed
    Score: 0.003
  81. Cleavage of the retinal pigment epithelium-specific protein RPE65 under oxidative stress. Int J Biol Macromol. 2010 Aug 01; 47(2):104-8.
    View in: PubMed
    Score: 0.003
  82. Menstrual influence on surgical cure of breast cancer. Lancet. 1990 Apr 21; 335(8695):984.
    View in: PubMed
    Score: 0.003
  83. More evidence for circadian rhythm effects in cancer chemotherapy: the fluoropyrimidine story. Cancer Cells. 1990 Mar; 2(3):65-8.
    View in: PubMed
    Score: 0.003
  84. Local immunosuppression of the vascularized graft. Surgery. 1990 Feb; 107(2):209-14.
    View in: PubMed
    Score: 0.003
  85. Circadian-based infusional FUDR therapy. Oncol Nurs Forum. 1990 Jan-Feb; 17(1):49-56.
    View in: PubMed
    Score: 0.003
  86. Cancer chronotherapy: a drug delivery challenge. Prog Clin Biol Res. 1990; 341A:1-10.
    View in: PubMed
    Score: 0.003
  87. Outpatient time-specified infusion of fluoropyrimidines by implanted pump is less costly than flat delivery by external pump. Prog Clin Biol Res. 1990; 341B:397-409.
    View in: PubMed
    Score: 0.003
  88. Enhancement of respiratory sinus arrhythmia by moderate exercise. Prog Clin Biol Res. 1990; 341A:283-96.
    View in: PubMed
    Score: 0.003
  89. Oral temperature rhythmometry and substantial within-day variation in zidovudine levels following steady-state dosing in human immunodeficiency virus (HIV) infection. Prog Clin Biol Res. 1990; 341A:67-76.
    View in: PubMed
    Score: 0.003
  90. In this issue: circadian disruption and cancer. Integr Cancer Ther. 2009 Dec; 8(4):295-7.
    View in: PubMed
    Score: 0.003
  91. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol. 1989 Nov; 7(11):1710-9.
    View in: PubMed
    Score: 0.003
  92. Menstrual influence on surgical cure of breast cancer. Lancet. 1989 Oct 21; 2(8669):949-52.
    View in: PubMed
    Score: 0.003
  93. Neuroprotective role of erythropoietin by antiapoptosis in the retina. J Neurosci Res. 2009 Aug 01; 87(10):2365-74.
    View in: PubMed
    Score: 0.003
  94. Menstrual history and breast cancer surgery. Breast Cancer Res Treat. 1989 Jul; 13(3):278.
    View in: PubMed
    Score: 0.003
  95. Sinusoidal fetal heart rate pattern during breathing is related to the respiratory sinus arrhythmia: a case report. Am J Obstet Gynecol. 1989 Mar; 160(3):690-2.
    View in: PubMed
    Score: 0.003
  96. Hypothesis: primary antiangiogenic method proposed to treat early stage breast cancer. BMC Cancer. 2009 Jan 08; 9:7.
    View in: PubMed
    Score: 0.003
  97. Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS. 2008 Jul-Aug; 116(7-8):730-41.
    View in: PubMed
    Score: 0.003
  98. The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008 Nov; 19(11):1821-8.
    View in: PubMed
    Score: 0.003
  99. A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. Clin Colorectal Cancer. 2008 Mar; 7(2):134-9.
    View in: PubMed
    Score: 0.003
  100. Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion. J Urol. 1988 Feb; 139(2):259-62.
    View in: PubMed
    Score: 0.003
  101. Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma. Semin Surg Oncol. 1988; 4(2):110-5.
    View in: PubMed
    Score: 0.003
  102. Time-dependent disposition of cyclosporine after pancreas transplantation, and application of chronopharmacokinetics to improve immunosuppression. Pharmacotherapy. 1988; 8(1):47-51.
    View in: PubMed
    Score: 0.003
  103. The rationale for non-zero-order drug delivery using automatic, computer-based drug delivery systems (chronotherapy). J Biol Response Mod. 1987 Dec; 6(6):587-98.
    View in: PubMed
    Score: 0.003
  104. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol. 2007 Dec; 4(12):699-710.
    View in: PubMed
    Score: 0.003
  105. Racial disparities in breast cancer outcome: insights into host-tumor interactions. Cancer. 2007 Nov 01; 110(9):1880-8.
    View in: PubMed
    Score: 0.003
  106. High-dose intensity, circadian-timed doxorubicin and cisplatin adjuvant chemotherapy for bladder cancer. Cancer Treat Rep. 1987 Oct; 71(10):915-9.
    View in: PubMed
    Score: 0.003
  107. Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):852-7.
    View in: PubMed
    Score: 0.003
  108. High-dose intensity systemic therapy of metastatic bladder cancer. J Clin Oncol. 1987 Mar; 5(3):450-5.
    View in: PubMed
    Score: 0.003
  109. Comment to "Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and intact primary tumor" by G V Babiera, R Rao, L Feng, F Meric-Bernstam, H M Kuerer, S E Singletary, K K Hunt, M I Ross, K M Gwyn, B W Feig, F C Ames, G N Horthobagyi. Ann Surg Oncol 2006;13:776-782. Ann Surg Oncol. 2007 Apr; 14(4):1519-20.
    View in: PubMed
    Score: 0.003
  110. Circadian pattern of continuous FUDR infusion reduces toxicities. Prog Clin Biol Res. 1987; 227B:357-73.
    View in: PubMed
    Score: 0.003
  111. Chemotherapy-induced vomiting: circadian drug timing as a source of predictable within-patient variability. Cancer Treat Rep. 1986 Nov; 70(11):1347-8.
    View in: PubMed
    Score: 0.003
  112. Allometric scaling law questions the traditional mechanical model for axillary lymph node involvement in breast cancer. J Clin Oncol. 2006 Sep 20; 24(27):4391-6.
    View in: PubMed
    Score: 0.003
  113. Comment to Anderson WF, Jatoi I, Devesa SS: distinct breast cancer incidence and prognostic patterns in the NCI'S SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127-137, 2005. Breast Cancer Res Treat. 2006 Jun; 97(3):341-3.
    View in: PubMed
    Score: 0.003
  114. Chemotherapy via implanted infusion pump: new perspectives for delivery of long-term continuous treatment. Oncol Nurs Forum. 1986 Mar-Apr; 13(2):17-24.
    View in: PubMed
    Score: 0.003
  115. Sociodemographic determinants of cancer treatment health literacy. Cancer. 2006 Feb 01; 106(3):726-7; author reply 727.
    View in: PubMed
    Score: 0.002
  116. Advanced transitional cell bladder cancer: a treatable disease. Semin Surg Oncol. 1986; 2(2):76-89.
    View in: PubMed
    Score: 0.002
  117. Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: animal findings and preliminary clinical experiences. Chronobiol Int. 1986; 3(1):55-64.
    View in: PubMed
    Score: 0.002
  118. Cancer chronomics III. Chronomics for cancer, aging, melatonin and experimental therapeutics researchers. J Exp Ther Oncol. 2006; 6(1):73-84.
    View in: PubMed
    Score: 0.002
  119. Utility of non-invasive instantaneous screening test for drug-induced cardiac damage. J Clin Oncol. 1985 Oct; 3(10):1438-9.
    View in: PubMed
    Score: 0.002
  120. Comment to Jatoi et al. report. Breast Cancer Res Treat. 2005 Sep; 93(1):1-2.
    View in: PubMed
    Score: 0.002
  121. Lack of antiemetic effect of high-dose metoclopramide. J Clin Oncol. 1985 Sep; 3(9):1273-6.
    View in: PubMed
    Score: 0.002
  122. Distinguishing between renal allograft rejection and cyclosporin nephrotoxicity. Lancet. 1985 Aug 31; 2(8453):501.
    View in: PubMed
    Score: 0.002
  123. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol. 2005 Sep; 16(9):1449-57.
    View in: PubMed
    Score: 0.002
  124. Circadian timing of cancer chemotherapy. Science. 1985 Apr 05; 228(4695):73-5.
    View in: PubMed
    Score: 0.002
  125. Cisplatin neurotoxicity: failure to demonstrate vitamin B12 inactivation. Cancer Treat Rep. 1985 Apr; 69(4):453-5.
    View in: PubMed
    Score: 0.002
  126. Does surgery unfavourably perturb the "natural history" of early breast cancer by accelerating the appearance of distant metastases? Eur J Cancer. 2005 Mar; 41(4):508-15.
    View in: PubMed
    Score: 0.002
  127. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005 Jan; 41(1):88-96.
    View in: PubMed
    Score: 0.002
  128. Recent translational research: computational studies of breast cancer. Breast Cancer Res. 2005; 7(1):37-40.
    View in: PubMed
    Score: 0.002
  129. Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour. Breast Cancer Res. 2004; 6(6):R689-96.
    View in: PubMed
    Score: 0.002
  130. 24-hour mean pulse. Simple predictor of doxorubicin-induced cardiac damage. Am J Med. 1984 Sep; 77(3):399-406.
    View in: PubMed
    Score: 0.002
  131. The respiratory sinus arrhythmia: a measure of cardiac age. Science. 1984 Jun 01; 224(4652):1001-4.
    View in: PubMed
    Score: 0.002
  132. Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res. 2004; 6(4):R372-4.
    View in: PubMed
    Score: 0.002
  133. Lack of age-dependent cisplatin nephrotoxicity. Am J Med. 1984 Apr; 76(4):579-84.
    View in: PubMed
    Score: 0.002
  134. Circadian mesor of recumbent pulse--cost-effective predictor of doxorubicin-induced congestive heart failure. Chronobiol Int. 1984; 1(1):59-66.
    View in: PubMed
    Score: 0.002
  135. Menopausal status dependence of early mortality reduction due to diagnosis of smaller breast cancers (T1 v T2-T3): relevance to screening. J Clin Oncol. 2004 Jan 01; 22(1):102-7.
    View in: PubMed
    Score: 0.002
  136. The clinical application of chronobiology to oncology. Am J Anat. 1983 Dec; 168(4):519-42.
    View in: PubMed
    Score: 0.002
  137. Circadian rhythmicity of polyamine urinary excretion. Cancer Res. 1983 Aug; 43(8):3944-7.
    View in: PubMed
    Score: 0.002
  138. Circadian time dependence of cisplatin urinary kinetics. Clin Pharmacol Ther. 1982 Sep; 32(3):330-9.
    View in: PubMed
    Score: 0.002
  139. Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res. 2001 Mar; 92(3):328-36.
    View in: PubMed
    Score: 0.002
  140. Unusual pigmentary changes associated with 5-fluorouracil therapy. Cutis. 1980 Aug; 26(2):181-82.
    View in: PubMed
    Score: 0.002
  141. Subcutaneous heparin-induced thrombocytopenia. Arch Intern Med. 1978 Oct; 138(10):1489-91.
    View in: PubMed
    Score: 0.001
  142. Platelet hyperaggregability and thrombocythemia. Ann Intern Med. 1978 Jun; 88(6):845-6.
    View in: PubMed
    Score: 0.001
  143. Thrombocytopenia induced by low-dose subcutaneous heparin. Lancet. 1977 Dec 17; 2(8051):1286.
    View in: PubMed
    Score: 0.001
  144. Current status of the therapy of advanced renal carcinoma. J Surg Oncol. 1977; 9(3):277-88.
    View in: PubMed
    Score: 0.001
  145. Letter: Serpentine supravenous fluorouracil hyperpigmentation. JAMA. 1976 Jul 12; 236(2):138.
    View in: PubMed
    Score: 0.001
  146. L-asparaginase activity in acute nonlymphocytic leukemia. Cancer Treat Rep. 1976 Jul; 60(7):966-7.
    View in: PubMed
    Score: 0.001
  147. Irreversible inactivation of interleukin 2 in a pump-based delivery environment. Proc Natl Acad Sci U S A. 1996 May 28; 93(11):5460-5.
    View in: PubMed
    Score: 0.001
  148. Serpentine supravenous 5-fluorouracil (NSC-19893) hyperpigmentation. Cancer Treat Rep. 1976 May; 60(5):639.
    View in: PubMed
    Score: 0.001
  149. The "other" asparaginase. Med Pediatr Oncol. 1976; 2(4):441-2.
    View in: PubMed
    Score: 0.001
  150. Steroid-responsive interstitial lung disease in patients receiving 2'-deoxy-5-fluorouridine-infusion chemotherapy. A report of three cases. Cancer. 1995 May 15; 75(10):2558-64.
    View in: PubMed
    Score: 0.001
  151. Lymphocyturia in human renal allograft rejection. Arch Surg. 1972 Sep; 105(3):424-6.
    View in: PubMed
    Score: 0.001
  152. A pharmacist's primer on chronotherapeutics. Am Pharm. 1992 Mar; NS32(3):77-83.
    View in: PubMed
    Score: 0.001
  153. Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology. 1991 Aug; 101(2):410-5.
    View in: PubMed
    Score: 0.001
  154. Circadian rhythm alteration in HIV infected subjects. Prog Clin Biol Res. 1990; 341A:437-49.
    View in: PubMed
    Score: 0.001
  155. The chronopharmacokinetics of cyclosporine and its metabolites in recipients of pancreas allografts. Transplant Proc. 1988 Apr; 20(2 Suppl 2):471-7.
    View in: PubMed
    Score: 0.001
  156. Circadian characteristics of dialyzable and non-dialyzable human urinary electrolytes, trace elements and total solids. Chronobiol Int. 1988; 5(2):175-84.
    View in: PubMed
    Score: 0.001
  157. [Biological rhythms and tumor markers in man. With special reference to the carcinoembryonic antigen (CEA) and alpha fetoprotein (AFP) in digestive system tumors]. Acta Gastroenterol Belg. 1987 Jan-Feb; 50(1):12-21.
    View in: PubMed
    Score: 0.001
  158. Cancer-associated alteration of circadian rhythms in carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in humans. Anticancer Res. 1986 Sep-Oct; 6(5):1137-44.
    View in: PubMed
    Score: 0.001
  159. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 1984 Jul; 34(7):934-8.
    View in: PubMed
    Score: 0.001
  160. Chronic lymphocytic leukemia in association with a second lymphoproliferative disorder: response to chemotherapy in two cases. Med Pediatr Oncol. 1979; 7(2):111-6.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.